<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847583</url>
  </required_header>
  <id_info>
    <org_study_id>Q203-COVID-P2-ZA001</org_study_id>
    <nct_id>NCT04847583</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients</brief_title>
  <official_title>A Phase 2 Open-Label, Randomized Controlled Trial to Evaluate the Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec in Participants With Moderate COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qurient Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qurient Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, randomized controlled trial to determine the effects of&#xD;
      Telacebec (Q203) on inhibition of leukotriene production, clinical change, pharmacokinetics,&#xD;
      and safety in participants with moderate COVID-19 disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker change</measure>
    <time_frame>Day 1 and 14</time_frame>
    <description>Percentage Inhibition of whole blood Leukotriene B4 (LTB4) production at 4 hours post dose SoC versus SoC plus telacebec</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>COVID-19 Virus Infection</condition>
  <arm_group>
    <arm_group_label>Telacebec (Q203) with COVID-19 standard of care (SoC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 Standard of care (SoC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telacebec</intervention_name>
    <description>Telacebec 100 mg tablet</description>
    <arm_group_label>Telacebec (Q203) with COVID-19 standard of care (SoC)</arm_group_label>
    <other_name>Q203</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COVID-19 Standard of care</intervention_name>
    <description>The Standard of Care treatment and administration thereof will be determined by the Investigator</description>
    <arm_group_label>COVID-19 Standard of care (SoC)</arm_group_label>
    <arm_group_label>Telacebec (Q203) with COVID-19 standard of care (SoC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written, informed consent prior to all study-related procedures.&#xD;
&#xD;
          2. Provide written, informed consent to undergo Human Immunodeficiency Virus (HIV)&#xD;
             testing.&#xD;
&#xD;
          3. Willingness and ability to attend scheduled visits and undergo study assessments.&#xD;
&#xD;
          4. Able and willing to measure their oxygen saturation level and temperature, record&#xD;
             their COVID-19 symptoms and complete a patient diary.&#xD;
&#xD;
          5. Male or female aged 18 years or older.&#xD;
&#xD;
          6. Confirmed and documented SARS-CoV-2 infection, defined as RT-PCR laboratory&#xD;
             confirmation.&#xD;
&#xD;
          7. Clinical and/or radiological findings indicative of moderate COVID-19 disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe or critical COVID-19 disease at enrollment (Day 1) (per NIH Treatment Guideline&#xD;
             categorization) as determined by the Investigator.&#xD;
&#xD;
          2. Inability to swallow oral medication.&#xD;
&#xD;
          3. Concurrent known asthma, active tuberculosis or tuberculosis within the last 3 months,&#xD;
             or any other condition that could compromise the well-being of the participant, or&#xD;
             prevent, limit or confound protocol specified assessments, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          4. Female Participant who is pregnant, breast-feeding, or planning to conceive a child&#xD;
             within the anticipated period of participating in the study or within 6 months after&#xD;
             last dose of study medication. Males planning to conceive a child during the study or&#xD;
             within 6 months of cessation of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qurient Clinical Trial Information</last_name>
    <phone>+82-31-8060-1610</phone>
    <phone_ext>KST</phone_ext>
    <email>clinicaltrial_info@qurient.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KwaPhila Health Solutions</name>
      <address>
        <city>Durban</city>
        <state>Kwa-Zula Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TASK Eden</name>
      <address>
        <city>George</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

